Summary
Provides Saudi-specific guidance for AI/ML medical devices used to diagnose, manage, or predict disease from medical data. Addresses intended-use classification, marketing-authorisation documentation, clinical association and technical and clinical validation, risk management, quality systems, post-market planning, and change notification. Issued in 2023; included here as an older, health-AI-specific gap rather than a new policy.
Healthcare Implications
Manufacturers seeking to market covered AI/ML devices in Saudi Arabia should plan evidence, validation, risk controls, quality documentation, and change management against the SFDA guidance and underlying medical-device requirements. It is interpretive guidance, not a separate new law.